RyR Channel Stabilization via FKBP Binding Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells, such as cardiac and skeletal muscular disorders, are inadequate in addressing the maladaptive responses and calcium leaks caused by PKA hyperphosphorylation of RyR channels, leading to arrhythmias and muscle dysfunction.
Innovation Solution
Development of compounds represented by the structure of formula I-k, which modulate the binding of FKBP proteins to PKA-phosphorylated RyR channels, thereby reducing the open probability of RyR channels and stabilizing the channel complex, thereby preventing calcium leaks and enhancing the affinity of FKBP proteins for phosphorylated RyR channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If PKA phosphorylation of RyR channels is increased to enhance cardiac contractility during stress, then cardiac performance is improved, but calcium leak and arrhythmia risk increase
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that bind to the RyR channel-calstabin complex. These compounds act as mediators between the phosphorylated RyR channel and calstabin, preventing calstabin dissociation even when PKA phosphorylation occurs. This allows the system to maintain both enhanced contractility (through PKA phosphorylation) and channel stability (through compound-mediated prevention of calstabin loss), thereby resolving the contradiction between power and reliability.
2Productivity
If calstabin binding to RyR channels is reduced due to PKA phosphorylation, then RyR open probability increases improving calcium release, but channel stability decreases leading to calcium leak
Solution Approach 1:
The patent employs compounds that preemptively bind to the RyR channel-calstabin complex before PKA-mediated phosphorylation can cause calstabin dissociation. By establishing this protective binding interaction in advance, the compound prevents the harmful dissociation event while allowing the beneficial calcium release to proceed, thus maintaining both productivity and stability simultaneously.
3Reliability
If FKBP protein affinity for phosphorylated RyR channels is low, then channel modulation is insufficient, but high affinity binding may interfere with normal channel gating
Solution Approach 1:
The patent utilizes compounds with optimized binding parameters that allow them to bind selectively to the phosphorylated RyR channel-calstabin complex without interfering with normal channel gating. By carefully tuning the binding affinity and specificity parameters of these small molecules, they achieve effective modulation of unstable channels while maintaining physiological channel function, thus resolving the contradiction between modulation efficacy and gating interference.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention provides compounds of Formula I, (I) and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.